Your browser doesn't support javascript.
loading
Assessment of serum endocan levels in patients with beta-thalassemia minor
Khanmammadov, Nijat; Zorlu, Mehmet; Ozer, Omer Faruk; Karatoprak, Cumali; Kiskaç, Muharrem; Çakirca, Mustafa.
  • Khanmammadov, Nijat; Bezmialem Vakif University. Faculty of Medicine. Internal Medicine Clinic. Istanbul. TR
  • Zorlu, Mehmet; Bezmialem Vakif University. Faculty of Medicine. Internal Medicine Clinic. Istanbul. TR
  • Ozer, Omer Faruk; Bezmialem Vakif University. Faculty of Medicine. Department of Medical Biochemistry Clinic. Istanbul. TR
  • Karatoprak, Cumali; Bezmialem Vakif University. Faculty of Medicine. Internal Medicine Clinic. Istanbul. TR
  • Kiskaç, Muharrem; Bezmialem Vakif University. Faculty of Medicine. Internal Medicine Clinic. Istanbul. TR
  • Çakirca, Mustafa; Bezmialem Vakif University. Faculty of Medicine. Internal Medicine Clinic. Istanbul. TR
Rev. Assoc. Med. Bras. (1992) ; 68(2): 147-151, Feb. 2022. tab
Article in English | LILACS | ID: biblio-1365347
ABSTRACT
SUMMARY

OBJECTIVE:

Beta-thalassemia minor is a blood disease caused by a hereditary decrease in beta-globin synthesis, frequently leading to hypochromic microcytic anemia. Formerly called endothelial cell-specific molecule 1, endocan is a proteoglycan released by vascular endothelial cells in many organs. Our aim was to investigate the relationship between the beta-thalassemia minor patients and the healthy control group in terms of serum endocan level.

METHODS:

The study was performed in a total of 80 subjects. They were divided into two groups, the beta-thalassemia minor group (n=40) and the healthy control group (n=40). Serum endocan levels, age, sex, body mass index value, and tobacco use data of these groups were compared.

RESULTS:

No statistically significant difference was detected between the two groups in terms of age, sex, and body mass index values (p>0.05). Endocan levels were measured to be 206.85±88.1 pg/mL in the beta-thalassemia minor group and 236.1±162.8 pg/mL in the control group with no significant difference between the groups in terms of serum endocan levels (p>0.05).

CONCLUSIONS:

In our study, there was no change in endocan level in beta-thalassemia minor. This might be because serum endocan levels are affected by multi-factorial reasons. Serum endocan levels may be altered secondarily to decreased beta-globin chain, increased sympathetic activity due to anemia, or platelet dysfunction induced by oxidative stress in beta-thalassemia minor. Further multicenter studies involving more patients are necessary to demonstrate this.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Proteoglycans / Beta-Thalassemia / Neoplasm Proteins Type of study: Controlled clinical trial Limits: Humans Language: English Journal: Rev. Assoc. Med. Bras. (1992) Year: 2022 Type: Article Affiliation country: Turkey Institution/Affiliation country: Bezmialem Vakif University/TR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Proteoglycans / Beta-Thalassemia / Neoplasm Proteins Type of study: Controlled clinical trial Limits: Humans Language: English Journal: Rev. Assoc. Med. Bras. (1992) Year: 2022 Type: Article Affiliation country: Turkey Institution/Affiliation country: Bezmialem Vakif University/TR